CD34 and systemic sclerosis: Finally, since the subcutaneous bleomycin mouse model is widely used in the development of novel therapies for SSc [37,56], we believe that verifying if the efficacy of the tested therapeutic approaches associates with a regeneration of the dermal networks of TCs/CD34+ stromal cells might provide new valuable insights into this still enigmatic cellular entity of the skin microenvironment.